Are GPCRs still a source of new targets?

Journal of Biomolecular Screening

Volumn 18, Issue 9, 2013, Pages 947-966

  Garland, Stephen L ^a  

^a Stevenage Bioscience Catalyst   (United Kingdom)

Author keywords

chemogenomics; functional selectivity; lead discovery; review

Indexed keywords

ACLIDINIUM BROMIDE; ADENOSINE RECEPTOR; ALCAFTADINE; AZILSARTAN; AZILSARTAN MEDOXOMIL; BETA ARRESTIN; CANNABINOID RECEPTOR AGONIST; CINACALCET; FINGOLIMOD; FRIZZLED PROTEIN; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; ICATIBANT; INDACATEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIRAGLUTIDE; LORCASERIN; LURASIDONE; MARAVIROC; MIRABEGRON; PASIREOTIDE; RECEPTOR ACTIVITY MODIFYING PROTEIN; TAFLUPROST; TEDUGLUTIDE; TESAMORELIN; TICAGRELOR; VILAZODONE; VISMODEGIB;

ALLERGIC CONJUNCTIVITIS; ANGIONEUROTIC EDEMA; BASAL CELL CARCINOMA; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; CALCIUM CELL LEVEL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CRYSTAL STRUCTURE; CUSHING DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HEART INFARCTION; HIGH THROUGHPUT SCREENING; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; MAJOR DEPRESSION; MULTIPLE SCLEROSIS; NONHUMAN; OVERACTIVE BLADDER; PHARMACOPHORE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SHORT BOWEL SYNDROME; WEIGHT REDUCTION; X RAY CRYSTALLOGRAPHY;

CHEMOGENOMICS; FUNCTIONAL SELECTIVITY; LEAD DISCOVERY; REVIEW;

ANILIDES; ANTINEOPLASTIC AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DATABASES, CHEMICAL; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; PROPYLENE GLYCOLS; PROTEIN BINDING; PYRIDINES; RECEPTORS, G-PROTEIN-COUPLED; SPHINGOSINE;

EID: 84884644197     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113498418     Document Type: Review

References (217)

1. Drews J.. Drug Discovery: A Historical Perspective. Science. 2000 ; 287: 1960-1964 (Pubitemid 30158662)
2. Wise A., Gearing K., Rees S.. Target Validation of G-protein Coupled Receptors. Drug Discov. Today. 2002 ; 7: 235-246 (Pubitemid 34143072)
3. Ma P., Zemmel R.. Value of Novelty?. Nat. Rev. Drug Discov. 2002 ; 1: 571-2
4. Overington J. P., Al-Lazikani B., Hopkins A. L.. How Many Drug Targets Are There?. Nat. Rev. Drug Discov. 2006 ; 5: 993-996 (Pubitemid 44835126)
5. Knox C., Law V., Jewison T., et al. DrugBank 3.0: A Comprehensive Resource for "Omics" Research on Drugs. Nucleic Acids Res. 2011 ; 39: D1035 - D1041
6. Wishart D. S., Knox C., Guo A. C., et al. DrugBank: A Knowledgebase For Drugs, Drug Actions and Drug Targets. Nucleic Acids Res. 2008 ; 36: D901 - D906
7. Wishart D. S., Knox C., Guo A. C., et al. DrugBank: A Comprehensive Resource for In Silico Drug Discovery and Exploration. Nucleic Acids Res. 2006 ; 34: D668 - D672
8. Garland S. L., Heightman T. D. Gene Family Focused Molecular Design. Lackey K. E., ed. Wiley: Hoboken, NJ ; 2009: 15-52.
9. Deftereos S. N., Andronis C., Friedla E. J., et al. Drug Repurposing and Adverse Event Prediction Using High-Throughput Literature Analysis. Systems Biol. Med. 2011 ; 3: 323-334
10. Padhy B. M., Gupta Y. K.. Drug Repositioning: Re-investigating Existing Drugs for New Therapeutic Indications. J. Postgrad. Med. 2011 ; 57: 153-160
11. Sardana D., Zhu C., Zhang M., et al. Drug Repositioning for Orphan Diseases. Briefings Bioinformatics. 2011 ; 12: 346-356
12. Barton N. P., Blaney F. E., Garland S. L., et al Comprehensive Medicinal Chemistry II - Volume 4. Triggle D. J. Taylor J. B., ed. Elsevier: Oxford ; 2007: 669-701.
13. Gloriam D. E., Foord S. M., Blaney F. E., et al. Definition of the G protein-Coupled Receptor Transmembrane Bundle Binding Pocket and Calculation of Receptor Similarities for Drug Design. J. Med. Chem. 2009 ; 52: 4429-4442
14. Garland S. L., Gloriam D. E.. A Ligand's View of Target Similarity: Chemogenomic Binding Site-Directed Techniques for Drug Discovery. Curr. Topics Med. Chem. 2011 ; 11: 1872-1881
15. Receveur J.-M., Bjurling E., Ulven T., et al. 4-Acylamino-and 4-Ureidobenzamides as Melanin-Concentrating Hormone (MCH) Receptor 1 Antagonists. Bioorg. Med. Chem. Lett. 2004 ; 14: 5075-5080 (Pubitemid 39233369)
16. Frimurer T. M., Ulven T., Elling C. E., et al. A Physicogenetic Method to Assign Ligand-Binding Relationships between 7TM Receptors. Bioorg. Med. Chem. Lett. 2005 ; 15: 3707-3712 (Pubitemid 41043167)
17. Martin R. E., Green L. G., Guba W., et al. Discovery of the First Nonpeptidic, Small-Molecule, Highly Selective Somatostatin Receptor Subtype 5 Antagonists: A Chemogenomics Approach. J. Med. Chem. 2007 ; 50: 6291-6294 (Pubitemid 350250414)
18. Guba W., Green L. G., Martin R. E., et al. From Astemizole to a Novel Hit Series of Small-Molecule Somatostatin 5 Receptor Antagonists via GPCR Affinity Profiling. J. Med. Chem. 2007 ; 50: 6295-6298 (Pubitemid 350250415)
19. Klabunde T., Giegerich C., Evers A.. Sequence-Derived Three-Dimensional Pharmacophore Models for G-protein-Coupled Receptors and Their Application in Virtual Screening. J. Med. Chem. 2009 ; 52: 2923-2932
20. Noguchi K., Ishii S., Shimizu T.. Identification of p2y9/GPR23 as a Novel G protein-Coupled Receptor for Lysophosphatidic Acid, Structurally Distant from the Edg Family. J. Biol. Chem. 2003 ; 278: 25600-25606 (Pubitemid 36835313)
21. Kotarsky K., Boketoft A., Bristulf J., et al. Lysophosphatidic Acid Binds to and Activates GPR92, a G protein-Coupled Receptor Highly Expressed In Gastrointestinal Lymphocytes. J. Pharmacol. Exp. Ther. 2006 ; 318: 619-628 (Pubitemid 44061237)
22. Yanagida K., Masago K., Nakanishi H., et al. Identification and Characterization of a Novel Lysophosphatidic Acid Receptor, p2y5/LPA6. J. Biol. Chem. 2009 ; 284: 17731-17741
23. Tulah A. S., Beghé B., Barton S. J., et al. Leukotriene B4 Receptor Locus Gene Characterisation and Association Studies in Asthma. BMC Med. Genet. 2012 ; 13: 110
24. Arkensteijn B. W. C., Berbée J. F. P., Rensen P. C. N., et al. The Apolipoprotein m-Sphingosine-1-Phosphate Axis: Biological Relevance in Lipoprotein Metabolism, Lipid Disorders and Atherosclerosis. Int. J. Mol. Sci. 2013 ; 14: 4419-4431
25. Camprubí-Robles M., Mair N., Andratsch M., et al. Sphingosine-1-Phosphate-Induced Nociceptor Excitation and Ongoing Pain Behavior in Mice and Humans Is Largely Mediated by S1P3 Receptor. J. Neurosci. 2013 ; 33: 2582-2592
26. Finley A., Chen Z., Esposito E., et al. Sphingosine 1-Phosphate Mediates Hyperalgesia via a Neutrophil-Dependent Mechanism. PloS One. 2013 ; 8: e55255
27. Dusaban S. S., Purcell N. H., Rockenstein E., et al. Phospholipase CÏμ Links G protein-Coupled Receptor Activation to Inflammatory Astrocytic Responses. Proc. Natl. Acad. Sci. U. S. A. 2013 ; 110: 3609-3614
28. Kluk M. J., Ryan K. P., Wang B., et al. Sphingosine-1-Phosphate Receptor 1 in Classical Hodgkin Lymphoma: Assessment of Expression and Role in Cell Migration. Lab. Invest. 2013 ; 94: 462-471
29. Lewis N. D., Haxhinasto S. A., Anderson S. M., et al. Circulating Monocytes Are Reduced by Sphingosine-1-Phosphate Receptor Modulators Independently of S1P3. J. Immunol. 2013 ; 190: 3533-3540
30. Lotinun S., Kiviranta R., Matsubara T., et al. Osteoclast-Specific Cathepsin K Deletion Stimulates S1P-Dependent Bone Formation. J. Clin. Invest. 2013 ; 123: 666-681
31. Montrose D. C., Scherl E. J., Bosworth B. P., et al. S1P1 Localizes to the Colonic Vasculature in Ulcerative Colitis and Maintains Blood Vessel Integrity. J. Lipid Res. 2013 ; 54: 843-851
32. Yang L., Yue S., Yang L., et al. Sphingosine Kinase/Sphingosine 1-Phosphate (S1P)/S1P Receptor Axis Is Involved in Liver Fibrosis-Associated Angiogenesis. J. Hepatol. 2013 ; 59: 114-123
33. Choi J. W., Herr D. R., Noguchi K., et al. LPA Receptors: Subtypes and Biological Actions. Annu. Rev. Pharmacol. Toxicol. 2010 ; 50: 157-186
34. Orosa B., González A., Mera A., et al. Lysophosphatidic Acid Receptor 1 Suppression Sensitizes Rheumatoid Fibroblast-Like Synoviocytes to Tumor Necrosis Factor-Induced Apoptosis. Arthritis Rheum. 2012 ; 64: 2460-2470
35. Gong Y. L., Tao C. J., Hu M., et al. Expression of Lysophosphatidic Acid Receptors and Local Invasiveness and Metastasis in Chinese Pancreatic Cancers. Curr. Oncol. 2012 ; 19: eS15 - eS21
36. Härmä V., Knuuttila M., Virtanen J., et al. Lysophosphatidic Acid and Sphingosine-1-Phosphate Promote Morphogenesis and Block Invasion of Prostate Cancer Cells in Three-Dimensional Organotypic Models. Oncogene. 2012 ; 31: 2075-2089
37. Hayashi M., Okabe K., Kato K., et al. Differential Function of Lysophosphatidic Acid Receptors in Cell Proliferation and Migration of Neuroblastoma Cells. Cancer Lett. 2012 ; 316: 91-96
38. Kato K., Fukui R., Okabe K., et al. Constitutively Active Lysophosphatidic Acid Receptor-1 Enhances the Induction of Matrix Metalloproteinase-2. Biochem. Biophys. Res. Commun. 2012 ; 417: 790-793
39. Kitayoshi M., Fukui R., Tanabe E., et al. Different Effects on Cell Proliferation and Migration Abilities of Endothelial Cells by LPA1 and LPA3 in Mammary Tumor FM3A Cells. J. Recept. Signal Transduction Res. 2012 ; 32: 209-213
40. Marshall J.-C. A., Collins J. W., Nakayama J., et al. Effect of Inhibition of the Lysophosphatidic Acid Receptor 1 on Metastasis and Metastatic Dormancy in Breast Cancer. J. Natl. Cancer Inst. 2012 ; 104: 1306-1319
41. Yang Y., Tang L.-Q., Wei W.. Prostanoids Receptors Signaling in Different Diseases/Cancers Progression. J. Recept. Signal Transduction Res. 2013 ; 33: 14-27
42. Soper J. H., Sugiyama S., Herbst-Robinson K., et al. Brain-Penetrant Tetrahydronaphthalene Thromboxane A2-Prostanoid (TP) Receptor Antagonists as Prototype Therapeutics for Alzheimer's Disease. ACS Chem. Neurosci. 2012 ; 3: 928-940
43. Li X., Tai H.-H.. Activation of Thromboxane A(2) Receptor (TP) Increases the Expression of Monocyte Chemoattractant Protein -1 (MCP-1)/Chemokine (C-C Motif) Ligand 2 (CCL2) and Recruits Macrophages to Promote Invasion of Lung Cancer Cells. PloS One. 2013 ; 8: e54073
44. Ahmad A. S., Maruyama T., Narumiya S., et al. PGE2 EP1 Receptor Deletion Attenuates 6-OHDA-Induced Parkinsonism in Mice: Old Switch, New Target. Neurotoxicity Res. 2013 ; 23: 260-266
45. Huang H. F. S., Shu P., Murphy T. F., et al. Significance of Divergent Expression of Prostaglandin EP4 and EP3 Receptors in Human Prostate Cancer. Mol. Cancer Res. 2013 ; 11: 427-439
46. Bourguet C. B., Goupil E., Tassy D., et al. Targeting the Prostaglandin F2α Receptor for Preventing Preterm Labor with Azapeptide Tocolytics. J. Med. Chem. 2011 ; 54: 6085-6097
47. Kim Y. T., Moon S. K., Maruyama T., et al. Prostaglandin FP Receptor Inhibitor Reduces Ischemic Brain Damage and Neurotoxicity. Neurobiol. Dis. 2012 ; 48: 58-65
48. Kazemi H., Rahgozar M., Speckmann E.-J., et al. Effect of Cannabinoid Receptor Activation on Spreading Depression. Iran. J. Basic Med. Sci. 2012 ; 15: 926-936
49. Wang Z.-Y., Wang P., Bjorling D. E.. Activation of Cannabinoid Receptor 2 Inhibits Experimental Cystitis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013 ; 304: R846 - R853
50. Battista N., Di Sabatino A., Di Tommaso M., et al. Altered Expression of Type-1 and Type-2 Cannabinoid Receptors in Celiac Disease. PloS One. 2013 ; 8: e62078
51. Siniscalco D., Sapone A., Giordano C., et al. Cannabinoid Receptor Type 2, but Not Type 1, Is Up-Regulated in Peripheral Blood Mononuclear Cells of Children Affected by Autistic Disorders. J. Autism Dev. Disord.. in press ;:
52. Busquets-Garcia A., Gomis-González M., Guegan T., et al. Targeting the Endocannabinoid System in the Treatment of Fragile X Syndrome. Nat. Med. 2013 ; 19: 603-607
53. Mallat A., Teixeira-Clerc F., Lotersztajn S.. Cannabinoid Signaling and Liver Therapeutics. J. Hepatol.. in press ;:
54. Zhang J., Wang S.-Y., Zhou J.-J., et al. Inhibitory Effects of Endocannabinoid on the Action Potential of Pacemaker Cells in Sinoatrial Nodes of Rabbits. Sheng Li Xue Bao. 2013 ; 65: 129-134
55. Hecht M., Harrer T., Büttner M., et al. Cytotoxic Effect of Efavirenz Is Selective against Cancer Cells and Associated with the Cannabinoid System. AIDS. in press ;:
56. Nulent T. J. W. K., Van Diest P. J., Van der Groep P., et al. Cannabinoid Receptor-2 Immunoreactivity Is Associated with Survival in Squamous Cell Carcinoma of the Head and Neck. Br. J. Oral Maxillofac. Surg.. in press ;:
57. Alemi F., Kwon E., Poole D. P., et al. The TGR5 Receptor Mediates Bile Acid-Induced Itch and Analgesia. J. Clin. Invest. 2013 ; 123: 1513-1530
58. Sato R.. Nomilin as an Anti-Obesity and Anti-Hyperglycemic Agent. Vitamins Hormones. 2013 ; 91: 425-439
59. Svensson P.-A., Olsson M., Assarsson J. C. A., et al. The TGR5 Gene Is Expressed in Human Subcutaneous Adipose Tissue and Is Associated with Obesity, Weight-Loss and Resting Metabolic Rate. Biochem. Biophys. Res. Commun. 2013 ; 433: 563-566
60. Habib A. M., Richards P., Rogers G. J., et al. Co-localisation and Secretion of Glucagon-Like Peptide 1 and Peptide YY from Primary Cultured Human L Cells. Diabetologia. 2013 ; 56: 1413-1416
61. McMahan R., Wang X. X., Cheng L. L., et al. Bile-Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Non-Alcoholic Fatty Liver Disease. J. Biol. Chem. 2013 ; 288: 11761-11770
62. Keitel V., Häussinger D.. TGR5 in Cholangiocytes. Curr. Opin. Gastroenterol. 2013 ; 29: 299-304
63. Péan N., Doignon I., Tordjmann T.. Bile Acids and Liver Carcinogenesis: TGR5 as a Novel Piece in the Puzzle?. Clin. Res. Hepatol. Gastroenterol. 2013 ; 37: 226-269
64. Wang X., Fu X., Van Ness C., et al. Bile Acid Receptors and Liver Cancer. Curr. Pathobiol. Rep. 2013 ; 1: 29-35
65. Rajagopal S., Kumar D. P., Mahavadi S., et al. Activation of G protein-Coupled Bile Acid Receptor, TGR5, Induces Smooth Muscle Relaxation via Both Epac- and PKA-Mediated Inhibition of RhoA/Rho Kinase Pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 2013 ; 304: G527 - G535
66. Hoyer F. F., Albrecht L., Nickenig G., et al. Selective Inhibition of Leukotriene Receptor BLT-2 Reduces Vascular Oxidative Stress and Improves Endothelial Function in ApoE-/- Mice. Mol. Cell. Biochem. 2012 ; 359: 25-31
67. Oyoshi M. K., He R., Li Y., et al. Leukotriene B4-Driven Neutrophil Recruitment to the Skin Is Essential for Allergic Skin Inflammation. Immunity. 2012 ; 37: 747-758
68. Park M. K., Park Y., Shim J., et al. Novel Involvement of Leukotriene B4 Receptor 2 through ERK Activation by PP2A Down-regulation in Leukotriene B4-Induced Keratin Phosphorylation and Reorganization of Pancreatic Cancer Cells. Biochim. Biophys. Acta. 2012 ; 1823: 2120-2129
69. Pettipher R., Vinall S. L., Xue L., et al. Pharmacologic Profile of OC000459, a Potent, Selective, and Orally Active D Prostanoid Receptor 2 Antagonist That Inhibits Mast Cell-Dependent Activation of T Helper 2 Lymphocytes and Eosinophils. J. Pharmacol. Exp. Ther. 2012 ; 340: 473-482
70. Seo J.-M., Park S., Kim J.-H.. Leukotriene B4 Receptor-2 Promotes Invasiveness and Metastasis of Ovarian Cancer Cells through Signal Transducer and Activator of Transcription 3 (STAT3)-Dependent Up-regulation of Matrix Metalloproteinase 2. J. Biol. Chem. 2012 ; 287: 13840-13849
71. Waki H., Hendy E. B., Hindmarch C. C. T., et al. Excessive Leukotriene B4 in Nucleus Tractus Solitarii Is Prohypertensive in Spontaneously Hypertensive Rats. Hypertension. 2013 ; 61: 194-201
72. Wang L., Zhao L., Lv J., et al. BLT1-Dependent Alveolar Recruitment of CD4(+)CD25(+) Foxp3(+) Regulatory T Cells Is Important for Resolution of Acute Lung Injury. Am. J. Respir. Crit. Care Med. 2012 ; 186: 989-998
73. Demoor T., Bracke K. R., Dupont L. L., et al. The Role of ChemR23 in the Induction and Resolution of Cigarette Smoke-Induced Inflammation. J. Immunol. 2011 ; 186: 5457-5467
74. Gao L., Faibish D., Fredman G., et al. Resolvin E1 and Chemokine-Like Receptor 1 Mediate Bone Preservation. J. Immunol. 2013 ; 190: 689-694
75. Bondue B., Vosters O., De Nadai P., et al. ChemR23 Dampens Lung Inflammation and Enhances Anti-Viral Immunity in a Mouse Model of Acute Viral Pneumonia. PLoS Pathogens. 2011 ; 7: e1002358
76. Iannone F., Lapadula G.. Chemerin/ChemR23 Pathway: A System beyond Chemokines. Arthritis Res. Ther. 2011 ; 13: 104
77. Christiansen E., Due-Hansen M. E., Urban C., et al. Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability. J. Med. Chem. 2013 ; 56: 982-992
78. Koch L.. Diabetes: FFAR1 Activation Improves Glycemia. Nat. Rev. Endocrinol. 2012 ; 8: 257
79. Luo J., Swaminath G., Brown S. P., et al. A Potent Class of GPR40 Full Agonists Engages the Enteroinsular Axis to Promote Glucose Control in Rodents. PloS One. 2012 ; 7: e46300
80. Wagner R., Kaiser G., Gerst F., et al. Reevaluation of Fatty Acid Receptor 1 (FFAR1/GPR40) as Drug Target for the Stimulation of Insulin Secretion in Humans. Diabetes. 2013 ; 62: 2106-2011
81. Zhao P., Abood M. E.. GPR55 and GPR35 and Their Relationship to Cannabinoid and Lysophospholipid Receptors. Life Sci. 2012 ; 92: 453-457
82. Pérez-Gómez E., Andradas C., Flores J. M., et al. The Orphan Receptor GPR55 Drives Skin Carcinogenesis and Is Upregulated in Human Squamous Cell Carcinomas. Oncogene. 2012 ; 32: 2534-2542
83. Wu C.-S., Chen H., Sun H., et al. GPR55, a G-protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination. PloS One. 2013 ; 8: e60314
84. Li K., Fichna J., Schicho R., et al. A Role for O-1602 and G protein-Coupled Receptor GPR55 in the Control of Colonic Motility in Mice. Neuropharmacology. 2013 ; 71: 255-263
85. Ryder C., McColl K., Zhong F., et al. Acidosis Promotes Bcl-2 Family-Mediated Evasion of Apoptosis: Involvement of Acid-Sensing G protein-Coupled Receptor Gpr65 Signaling to Mek/Erk. J. Biol. Chem. 2012 ; 287: 27863-27875
86. Castellone R. D., Leffler N. R., Dong L., et al. Inhibition of Tumor Cell Migration and Metastasis by the Proton-Sensing GPR4 Receptor. Cancer Lett. 2011 ; 312: 197-208
87. Chen A., Dong L., Leffler N. R., et al. Activation of GPR4 by Acidosis Increases Endothelial Cell Adhesion through the cAMP/Epac Pathway. PloS One. 2011 ; 6: e27586
88. Dong L., Li Z., Leffler N. R., et al. Acidosis Activation of the Proton-Sensing GPR4 Receptor Stimulates Vascular Endothelial Cell Inflammatory Responses Revealed by Transcriptome Analysis. PloS One. 2013 ; 8: e61991
89. Saxena H., Deshpande D. a, Tiegs B. C., et al. The GPCR OGR1 (GPR68) Mediates Diverse Signalling and Contraction of Airway Smooth Muscle in Response to Small Reductions in Extracellular pH. Br. J. Pharmacol. 2012 ; 166: 981-990
90. Muraki M., Imbe S., Santo H., et al. Effects of a Cysteinyl Leukotriene Dual 1/2 Receptor Antagonist on Antigen-Induced Airway Hypersensitivity and Airway Inflammation in a Guinea Pig Asthma Model. Int. Arch. Allergy Immunol. 2011 ; 155: 90-95
91. Ni N. C., Yan D., Ballantyne L. L., et al. A Selective Cysteinyl Leukotriene Receptor 2 Antagonist Blocks Myocardial Ischemia/Reperfusion Injury and Vascular Permeability in Mice. J. Pharmacol. Exp. Ther. 2011 ; 339: 768-778
92. Shi Q.-J., Xiao L., Zhao B., et al. Intracerebroventricular Injection of HAMI 3379, a Selective Cysteinyl Leukotriene Receptor 2 Antagonist, Protects against Acute Brain Injury after Focal Cerebral Ischemia in Rats. Brain Res. 2012 ; 1484: 57-67
93. Tsaoussoglou M., Lianou L., Maragozidis P., et al. Cysteinyl Leukotriene Receptors in Tonsillar B- and T-lymphocytes from Children with Obstructive Sleep Apnea. Sleep Med. 2012 ; 13: 879-885
94. Magnusson C., Bengtsson A. M., Liu M., et al. Regulation of Cysteinyl Leukotriene Receptor 2 Expression - A Potential Anti-Tumor Mechanism. PloS One. 2011 ; 6: e29060
95. Barajas-Espinosa A., Ni N. C., Yan D., et al. The Cysteinyl Leukotriene 2 Receptor Mediates Retinal Edema and Pathological Neovascularization in a Murine Model of Oxygen-Induced Retinopathy. FASEB J. 2012 ; 26: 1100-1109
96. Barrett N. A., Fernandez J. M., Maekawa A., et al. Cysteinyl Leukotriene 2 Receptor on Dendritic Cells Negatively Regulates Ligand-Dependent Allergic Pulmonary Inflammation. J. Immunol. 2012 ; 189: 4556-4565
97. Oyoshi M. K., He R., Kanaoka Y., et al. Eosinophil-Derived Leukotriene C4 Signals via Type 2 Cysteinyl Leukotriene Receptor to Promote Skin Fibrosis in a Mouse Model of Atopic Dermatitis. Proc. Natl. Acad. Sci. U. S. A. 2012 ; 109: 4992-4997
98. Iovino F., Brouwer M. C., Van de Beek D., et al. Signaling or Binding: The Role of the Platelet Activating Factor Receptor in Invasive Pneumococcal Disease. Cell. Microbiol. 2013 ; 15: 870-871
99. Motoyama N., Morita K., Kitayama T., et al. Pain-Releasing Action of Platelet-Activating Factor (PAF) Antagonists in Neuropathic Pain Animal Models and the Mechanisms of Action. Eur. J. Pain. in press ;:
100. Guerrero A. T., Zaperlon A. C., Vieira S. M., et al. The Role of PAF/PAFR Signaling in Zymosan-Induced Articular Inflammatory Hyperalgesia. Naunyn Schmiedeberg Arch. Pharmacol. 2013 ; 386: 51-59
101. Lacerda-Queiroz N., Rachid M. A., Teixeira M. M., et al. The Role of Platelet-Activating Factor Receptor (PAFR) in Lung Pathology during Experimental Malaria. Int. J. Parasitol. 2013 ; 43: 11-15
102. Balestrieri M. L., Servillo L., Esposito A., et al. Poor Glycaemic Control in Type 2 Diabetes Patients Reduces Endothelial Progenitor Cell Number by Influencing SIRT1 Signalling via Platelet-Activating Factor Receptor Activation. Diabetologia. 2013 ; 56: 162-172
103. Rios F. J. O., Koga M. M., Ferracini M., et al. Co-stimulation of PAFR and CD36 Is Required for oxLDL-Induced Human Macrophages Activation. PloS One. 2012 ; 7: e36632
104. Dupré D. J., Rola-Pleszczynski M., Stankova J.. Rescue of Internalization-Defective Platelet-Activating Factor Receptor Function by EBP50/NHERF1. J. Cell Commun. Signal. 2012 ; 6: 205-216
105. Onuchic A. C., Machado C. M. L., Saito R. F., et al. Expression of PAFR as Part of a Prosurvival Response to Chemotherapy: A Novel Target for Combination Therapy in Melanoma. Mediators Inflammation. 2012 ; 2012: 175408
106. Grant G. E., Rokach J., Powell W. S.. 5-Oxo-ETE and the OXE Receptor. Prostaglandins Other Lipid Mediat. 2009 ; 89: 98-104
107. Ahmed K.. Biological Roles and Therapeutic Potential of Hydroxy-Carboxylic Acid Receptors. Frontiers Endocrinol. 2011 ; 2: 51
108. Ahmed K., Tunaru S., Offermanns S.. GPR109A, GPR109B and GPR81, a Family of Hydroxy-Carboxylic Acid Receptors. Trends Pharmacol. Sci. 2009 ; 30: 557-562
109. Liu C., Wu J., Zhu J., et al. Lactate Inhibits Lipolysis in Fat Cells through Activation of an Orphan G-protein-Coupled Receptor, GPR81. J. Biol. Chem. 2009 ; 284: 2811-2822
110. Wanders D., Graff E. C., Judd R. L.. Effects of High Fat Diet on GPR109A and GPR81 Gene Expression. Biochem. Biophys. Res. Commun. 2012 ; 425: 278-283
111. Yokota Y., Inoue H., Matsumura Y., et al. Absence of LTB4/BLT1 Axis Facilitates Generation of Mouse GM-CSF-Induced Long-Lasting Antitumor Immunologic Memory by Enhancing Innate and Adaptive Immune Systems. Blood. 2012 ; 120: 3444-3454
112. Probe Reports from the NIH Molecular Libraries Program. National Institutes of Health: Bethesda, MD ; 2010 :
113. Gaulton A., Bellis L. J., Bento A. P., et al. ChEMBL: A Large-Scale Bioactivity Database for Drug Discovery. Nucleic Acids Res. 2012 ; 40: D1100 - D1107
114. TitusS.HuangW.MaruganJ.. Identification of Potent and Selective Thyroid Stimulating Hormone Receptor Agonists. Probe Reports from the NIH Molecular Libraries Program. 2010. http://www.ncbi.nlm.nih.gov/pubmed/21735603. Accessed April 28, 2013.
115. Moore S., Jaeschke H., Kleinau G., et al. Evaluation of Small-Molecule Modulators of the Luteinizing Hormone/Choriogonadotropin and Thyroid Stimulating Hormone Receptors: Structure-Activity Relationships and Selective Binding Patterns. J. Med. Chem. 2006 ; 49: 3888-3896 (Pubitemid 43967885)
116. Blad C. C., Van Veldhoven J. P. D., Klopman C., et al. Novel 3,6,7-substituted Pyrazolopyrimidines as Positive Allosteric Modulators for the Hydroxycarboxylic Acid Receptor 2 (GPR109A). J. Med. Chem. 2012 ; 55: 3563-3567
117. Boatman P. D., Lauring B., Schrader T. O., et al. (1aR,5aR)1a,3,5,5a- Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist That Lowers Free Fatty Acids in Humans. J. Med. Chem. 2012 ; 55: 3644-3666
118. Boatman P. D., Schrader T. O., Kasem M., et al. Potent Tricyclic Pyrazole Tetrazole Agonists of the Nicotinic Acid Receptor (GPR109a). Bioorg. Med. Chem. Lett. 2010 ; 20: 2797-2800
119. Ding F.-X., Shen H. C., Wilsie L. C., et al. Discovery of Pyrazolyl Propionyl Cyclohexenamide Derivatives as Full Agonists for the High Affinity Niacin Receptor GPR109A. Bioorg. Med. Chem. Lett. 2010 ; 20: 3372-3375
120. Huang X., Su J., Rao A. U., et al. SAR Studies of C2 Ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as Nicotinic Acid Receptor (NAR) Agonist. Bioorg. Med. Chem. Lett. 2012 ; 22: 854-858
121. Imbriglio J. E., Chang S., Liang R., et al. GPR109a Agonists. Part 2: Pyrazole-Acids as Agonists of the Human Orphan G-protein Coupled Receptor GPR109a. Bioorg. Med. Chem. Lett. 2010 ; 20: 4472-4474
122. Imbriglio J. E., DiRocco D., Bodner R., et al. The Discovery of High Affinity Agonists of GPR109a with Reduced Serum Shift and Improved ADME Properties. Bioorg. Med. Chem. Lett. 2011 ; 21: 2721-2724
123. Peters J.-U., Kühne H., Dehmlow H., et al. Pyrido Pyrimidinones as Selective Agonists of the High Affinity Niacin Receptor GPR109A: Optimization of In Vitro Activity. Bioorg. Med. Chem. Lett. 2010 ; 20: 5426-5430
124. Schmidt D., Smenton A., Raghavan S., et al. Anthranilic Acid Replacements in a Niacin Receptor Agonist. Bioorg. Med. Chem. Lett. 2010 ; 20: 3426-3430
125. Shen H. C., Ding F.-X., Raghavan S., et al. Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate. J. Med. Chem. 2010 ; 53: 2666-2670
126. Van Veldhoven J. P. D., Blad C. C., Artsen C. M., et al. Structure-Activity Relationships of Trans-Substituted-Propenoic Acid Derivatives on the Nicotinic Acid Receptor HCA2 (GPR109A). Bioorg. Med. Chem. Lett. 2011 ; 21: 2736-2739
127. Herbert M. R., Siegel D. L., Staszewski L., et al. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as Agonists of the Bile Acid Receptor TGR5. Bioorg. Med. Chem. Lett. 2010 ; 20: 5718-5721
128. Pellicciari R., Sato H., Gioiello A., et al. Nongenomic Actions of Bile Acids: Synthesis and Preliminary Characterization of 23- and 6,23-alkyl-substituted Bile Acid Derivatives as Selective Modulators for the G-protein Coupled Receptor TGR5. J. Med. Chem. 2007 ; 50: 4265-4268 (Pubitemid 47378826)
129. Genet C., Strehle A., Schmidt C., et al. Structure-Activity Relationship Study of Betulinic Acid, a Novel and Selective TGR5 Agonist, and Its Synthetic Derivatives: Potential Impact in Diabetes. J. Med. Chem. 2010 ; 53: 178-190
130. Pellicciari R., Gioiello A., Macchiarulo A., et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity. J. Med. Chem. 2009 ; 52: 7958-7961
131. Evans K. A., Budzik B. W., Ross S. A., et al. Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 Receptor Agonists. J. Med. Chem. 2009 ; 52: 7962-7965
132. Budzik B. W., Evans K. A., Wisnoski D. D., et al. Synthesis and Structure-Activity Relationships of a Series of 3-aryl-4-isoxazolecarboxamides as a New Class of TGR5 Agonists. Bioorg. Med. Chem. Lett. 2010 ; 20: 1363-1367
133. Katona B. W., Cummins C. L., Ferguson A. D., et al. Synthesis, Characterization, and Receptor Interaction Profiles of Enantiomeric Bile Acids. J. Med. Chem. 2007 ; 50: 6048-6058
134. Bulaj G., Green B. R., Lee H.-K., et al. Design, Synthesis, and Characterization of High-Affinity, Systemically-Active Galanin Analogues with Potent Anticonvulsant Activities. J. Med. Chem. 2008 ; 51: 8038-8047
135. Zhang L., Robertson C. R., Green B. R., et al. Structural Requirements for a Lipoamino Acid in Modulating the Anticonvulsant Activities of Systemically Active Galanin Analogues. J. Med. Chem. 2009 ; 52: 1310-1316
136. Robertson C. R., Scholl E. A., Pruess T. H., et al. Engineering Galanin Analogues That Discriminate between GalR1 and GalR2 Receptor Subtypes and Exhibit Anticonvulsant Activity following Systemic Delivery. J. Med. Chem. 2010 ; 53: 1871-1875
137. Sagi V. N., Liu T., Lu X., et al. Synthesis and Biological Evaluation of Novel Pyrimidine Derivatives as Sub-micromolar Affinity Ligands of GalR2. Bioorg. Med. Chem. Lett. 2011 ; 21: 7210-7215
138. Kobayashi T., Sasaki S., Tomita N., et al. 2-Acylamino-4,6- diphenylpyridine Derivatives as Novel GPR54 Antagonists with Good Brain Exposure and In Vivo Efficacy for Plasma LH Level in Male Rats. Bioorg. Med. Chem. 2010 ; 18: 5157-5171
139. Kobayashi T., Sasaki S., Tomita N., et al. Synthesis and Structure-Activity Relationships of 2-acylamino-4,6-diphenylpyridine Derivatives as Novel Antagonists of GPR54. Bioorg. Med. Chem. 2010 ; 18: 3841-3859
140. Tomita K., Oishi S., Ohno H., et al. Development of Novel G-protein-Coupled Receptor 54 Agonists with Resistance to Degradation by Matrix Metalloproteinase. J. Med. Chem. 2008 ; 51: 7645-7649
141. Wang Y., Jiao X., Kayser F., et al. The First Synthetic Agonists of FFA2: Discovery and SAR of Phenylacetamides as Allosteric Modulators. Bioorg. Med. Chem. Lett. 2010 ; 20: 493-498
142. Lewin A. H., Miller G. M., Gilmour B.. Trace Amine-Associated Receptor 1 Is a Stereoselective Binding Site for Compounds in the Amphetamine Class. Bioorg. Med. Chem. 2011 ; 19: 7044-7048
143. Lewin A. H., Navarro H. A., Mascarella S. W.. Structure-Activity Correlations for Beta-phenethylamines at Human Trace Amine Receptor 1. Bioorg. Med. Chem. 2008 ; 16: 7415-7423
144. Ko H., Fricks I., Ivanov A. A., et al. Structure-Activity Relationship of Uridine 5′-diphosphoglucose Analogues as Agonists of the Human P2Y14 Receptor. J. Med. Chem. 2007 ; 50: 2030-2039 (Pubitemid 46683056)
145. Ko H., Das A., Carter R. L., et al. Molecular Recognition in the P2Y(14) Receptor: Probing the Structurally Permissive Terminal Sugar Moiety of Uridine-5′-diphosphoglucose. Bioorg. Med. Chem. 2009 ; 17: 5298-5311
146. Oishi S., Misu R., Tomita K., et al. Activation of Neuropeptide FF Receptors by Kisspeptin Receptor Ligands. ACS Med. Chem. Lett. 2011 ; 2: 53-57
147. Chen H.-S., Kuo S.-C., Teng C.-M., et al. Synthesis and Antiplatelet Activity of Ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) Derivatives. Bioorg. Med. Chem. 2008 ; 16: 1262-1278 (Pubitemid 351200483)
148. Goodnow R. A., Hicks A., Sidduri A., et al. Discovery of Novel and Potent Leukotriene B4 Receptor Antagonists. Part 1. J. Med. Chem. 2010 ; 53: 3502-3516
149. Conde-Frieboes K., Thøgersen H., Lau J. F., et al. Identification and In Vivo and In Vitro Characterization of Long Acting and Melanocortin 4 Receptor (MC4-R) Selective α-Melanocyte-Stimulating Hormone (α-MSH) Analogues. J. Med. Chem. 2012 ; 55: 1969-1977
150. Baber J. C., Lowe R., Saunders J., et al. Automated Generation of Turn Mimetics: Proof of Concept Study for the MC4 Receptor. Bioorg. Med. Chem. 2012 ; 20: 3565-3574
151. Mayorov A. V, Cai M., Palmer E. S., et al. Cyclic Lactam Hybrid α-MSH/Agouti-Related Protein (AGRP) Analogues with Nanomolar Range Binding Affinities at the Human Melanocortin Receptors. Bioorg. Med. Chem. Lett. 2011 ; 21: 3099-3102
152. Hong Q., Bakshi R. K., Palucki B. L., et al. Discovery of a Piperazine Urea Based Compound as a Potent, Selective, Orally Bioavailable Melanocortin Subtype-4 Receptor Partial Agonist. Bioorg. Med. Chem. Lett. 2011 ; 21: 2330-2334
153. Conde-Frieboes K., Ankersen M., Breinholt J., et al. Serendipitous Discovery of a New Class of Agonists for the Melanocortin 1 and 4 Receptors and a New Class of Cyclophanes. Bioorg. Med. Chem. Lett. 2011 ; 21: 1459-1463
154. He S., Ye Z., Dobbelaar P. H., et al. Spiroindane Based Amides as Potent and Selective MC4R Agonists for the Treatment of Obesity. Bioorg. Med. Chem. Lett. 2010 ; 20: 4399-4405
155. BridgesT. M.ReidP. R.LewisL. M.; et al.. Discovery and Development of a Second Highly Selective M1 Positive Allosteric Modulator (PAM). Probe Reports from the NIH Molecular Libraries Program. 2010. http://www.ncbi.nlm.nih.gov/ pubmed/21433394. Accessed April 28, 2013.
156. BridgesT. M.LewisL. M.DawsonE. S.; et al. Discovery and Development of a Highly Selective M1 Positive Allosteric Modulator (PAM). Probe Reports from the NIH Molecular Libraries Program. 2010. http://www.ncbi.nlm.nih.gov/pubmed/ 21433387. Accessed April 28, 2013.
157. BridgesT. M.LewisL. M.WeaverCD.; et al. Discovery of the First mAChR 5 (M5) Selective Ligand, an M5 Positive Allosteric Modulator (PAM). Probe Reports from the NIH Molecular Libraries Program. 2010. http://www.ncbi.nlm.nih.gov/ pubmed/21433383. Accessed April 28, 2013.
158. LewisL. M.BridgesT. M.NiswenderT. M.; et al. Discovery of a Highly Selective In Vitro and In Vivo M4 Positive Allosteric Modulator (PAM). Probe Reports from the NIH Molecular Libraries Program. 2010. http://www.ncbi.nlm.nih. gov/pubmed/21433380. Accessed April 28, 2013.
159. LindsleyCLewisMWeaverD. Discovery of a Highly Selective In Vitro and In Vivo M1 Allosteric Agonist Probe. Probe Reports from the NIH Molecular Libraries Program. 2010. http://www.ncbi.nlm.nih.gov/pubmed/21433356. Accessed April 28, 2013.
160. Melancon B. J., Gogliotti R. D., Tarr J. C., et al. Continued Optimization of the MLPCN Probe ML071 into Highly Potent Agonists of the hM1 Muscarinic Acetylcholine Receptor. Bioorg. Med. Chem. Lett. 2012 ; 22: 3467-3472
161. Melancon B. J., Hopkins C. R., Wood M. R., et al. Allosteric Modulation of Seven Transmembrane Spanning Receptors: Theory, Practice, and Opportunities for Central Nervous System Drug Discovery. J. Med. Chem. 2012 ; 55: 1445-1464
162. Venkatakrishnan A. J., Deupi X., Lebon G., et al. Molecular Signatures of G-protein-Coupled Receptors. Nature. 2013 ; 494: 185-194
163. Henen M. A., Coudevylle N., Geist L., et al. Toward Rational Fragment-Based Lead Design without 3D Structures. J. Med. Chem. 2012 ; 55: 7909-7919
164. Hanson M. a, Cherezov V., Griffith M. T., et al. A Specific Cholesterol Binding Site Is Established by the 2.8 A Structure of the Human Beta2-Adrenergic Receptor. Structure. 2008 ; 16: 897-905 (Pubitemid 351778384)
165. Fillion D., Cabana J., Guillemette G., et al. Structure of the Human AT1 Receptor Bound to Angiotensin II from Multiple Chemoselective Photoprobe
166. Ding X., Zhao X., Watts A.. G-protein-Coupled Receptor Structure, Ligand Binding and Activation as Studied by Solid-State NMR Spectroscopy. Biochem. J. 2013 ; 450: 443-457
167. Garland S. L., Blaney F. E. Burger's Medicinal Chemistry. Abraham D. J. Rotella D., ed. Wiley: Hoboken, NJ ; 2010 :
168. Roed S. N., Orgaard A., Jorgensen R., et al. Receptor Oligomerization in Family B1 of G-protein-Coupled Receptors: Focus on BRET Investigations and the Link between GPCR Oligomerization and Binding Cooperativity. Frontiers Endocrinol. 2012 ; 3: 62
169. Silberstein S. D.. Emerging Target-Based Paradigms to Prevent and Treat Migraine. Clin. Pharmacol. Ther. 2013 ; 93: 78-85
170. Luo G., Chen L., Conway C. M., et al. Discovery of (5S,6S,9R)-5-amino-6- (2,3-difluorophenyl)-6,7,8,9- tetrahydro- 5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in c. J. Med. Chem. 2012 ; 55: 10644-10651
171. Tozzi A., De Iure A., Di Filippo M., et al. Critical Role of Calcitonin Gene-Related Peptide Receptors in Cortical Spreading Depression. Proc. Natl. Acad. Sci. U. S. A. 2012 ; 109: 18985-18990
172. Andrews G., Jones C., Wreggett K. A.. An Intracellular Allosteric Site for a Specific Class of Antagonists of the CC Chemokine G protein-Coupled Receptors CCR4 and CCR5. Mol. Pharmacol. 2008 ; 73: 855-867 (Pubitemid 351397890)
173. Lebon G., Langmead C. J., Tehan B. G., et al. Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors. Mol. Pharmacol. 2009 ; 75: 331-341
174. Ragnarsson L., Wang C.-I. A., Andersson Å., et al. Conopeptide ρ-TIA Defines a New Allosteric Site on the Extracellular Surface of the α1B-adrenoceptor. J. Biol. Chem. 2013 ; 288: 1814-1827
175. Rocheville M., Garland S. L.. An Industrial Perspective on Positive Allosteric Modulation as a Means to Discover Safe and Effective Drugs. Drug Discov. Today Technol. 2010 ; 7: 87-94
176. Deupi X., Kobilka B.. Activation of G protein-Coupled Receptors. Adv. Protein Chem. 2007 ; 74: 137-166 (Pubitemid 47369749)
177. Siehler S.. G12/13-dependent Signaling of G-protein-Coupled Receptors: Disease Context and Impact on Drug Discovery. Expert Opin. Drug Discov. 2007 ; 2: 1591-1604 (Pubitemid 350285348)
178. Kozasa T., Hajicek N., Chow C. R., et al. Signalling Mechanisms of RhoGTPase Regulation by the Heterotrimeric G proteins G12 and G13. J. Biochem. 2011 ; 150: 357-369
179. Kobe F., Guseva D., Jensen T. P., et al. 5-HT7R/G12 Signaling Regulates Neuronal Morphology and Function in an Age-Dependent Manner. J. Neurosci. 2012 ; 32: 2915-2930
180. Obara Y., Ueno S., Yanagihata Y., et al. Lysophosphatidylinositol Causes Neurite Retraction via GPR55, G13 and RhoA in PC12 Cells. PloS One. 2011 ; 6: e24284
181. Shen B., Delaney M. K., Du X.. Inside-out, Outside-in, and Inside-outside-in: G protein Signaling in Integrin-Mediated Cell Adhesion, Spreading, and Retraction. Curr. Opin. Cell Biol. 2012 ; 24: 600-606
182. Takefuji M., Wirth A., Lukasova M., et al. G(13)-mediated Signaling Pathway Is Required for Pressure Overload-Induced Cardiac Remodeling and Heart Failure. Circulation. 2012 ; 126: 1972-1982
183. Yagi H., Tan W., Dillenburg-Pilla P., et al. A Synthetic Biology Approach Reveals a CXCR4-G13-Rho Signaling Axis Driving Transendothelial Migration of Metastatic Breast Cancer Cells. Sci. Signal. 2011 ; 4: ra60
184. Giannone F., Malpeli G., Lisi V., et al. The Puzzling Uniqueness of the Heterotrimeric G15 Protein and Its Potential beyond Hematopoiesis. J. Mol. Endocrinol. 2010 ; 44: 259-269
185. Milligan G., Kostenis E.. Heterotrimeric G-proteins: A Short History 2006. Br. J. Pharmacol 147 Suppl.: S46 - S55
186. DeWire S. M., Ahn S., Lefkowitz R. J., et al. Beta-arrestins and Cell Signaling. Annu. Rev. Physiol. 2007 ; 69: 483-510
187. Luttrell L. M., Gesty-Palmer D.. Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling. Pharmacol. Rev. 2010 ; 62: 305-330
188. Schmid C. L., Bohn L. M.. Physiological and Pharmacological Implications of Beta-arrestin Regulation. Pharmacol. Ther. 2009 ; 121: 285-293
189. Whalen E. J., Rajagopal S., Lefkowitz R. J.. Therapeutic Potential of β-arrestin- and G protein-Biased Agonists. Trends Mol. Med. 2011 ; 17: 126-139
190. Violin J. D., DeWire S. M., Yamashita D., et al. Selectively Engaging β-arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance. J. Pharmacol. Exp. Ther. 2010 ; 335: 572-579
191. Peprah K., Zhu X. Y., Eyunni S. V. K., et al. Multi-Receptor Drug Design: Haloperidol as a Scaffold for the Design and Synthesis of Atypical Antipsychotic Agents. Bioorg. Med. Chem. 2012 ; 20: 1291-1297
192. Kraemer S., Rajabi S. A., El Bounkari O., et al. Hetero-oligomerization of Chemokine Receptors: Diversity and Relevance for Function. Curr. Med. Chem. 2013 ; 20: 2524-2536
193. Liu J. J., Wang Y., Johnson M. G., et al. Optimization of Phenylacetic Acid Derivatives for Balanced CRTH2 and DP Dual Antagonists. Bioorg. Med. Chem. Lett. 2012 ; 22: 1686-1689
194. Gattrell W. T., Sambrook Smith C. P., Smith A. J.. An Example of Designed Multiple Ligands Spanning Protein Classes: Dual MCH-1R Antagonists/DPPIV Inhibitors. Bioorg. Med. Chem. Lett. 2012 ; 22: 2464-2469
195. Galvez T., Duthey B., Kniazeff J., et al. Allosteric Interactions between GB1 and GB2 Subunits Are Required for Optimal GABA(B) Receptor Function. EMBO J. 2001 ; 20: 2152-2159 (Pubitemid 32410585)
196. Comps-Agrar L., Kniazeff J., Nørskov-Lauritsen L., et al. The Oligomeric State Sets GABA(B) Receptor Signalling Efficacy. EMBO J. 2011 ; 30: 2336-2349
197. Ter Haar E., Koth C. M., Abdul-Manan N., et al. Crystal Structure of the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals the Site of Drug Antagonism. Structure. 2010 ; 18: 1083-1093
198. Bouschet T., Martin S., Henley J. M.. Receptor-Activity-Modifying Proteins Are Required for Forward Trafficking of the Calcium-Sensing Receptor to the Plasma Membrane. J. Cell Sci. 2005 ; 118: 4709-4720 (Pubitemid 41646381)
199. Meyer B. H., Segura J.-M., Martinez K. L., et al. FRET Imaging Reveals That Functional Neurokinin-1 Receptors Are Monomeric and Reside in Membrane Microdomains of Live Cells. Proc. Natl. Acad. Sci. U. S. A. 2006 ; 103: 2138-2143 (Pubitemid 43271636)
200. Terrillon S., Bouvier M.. Roles of G-protein-Coupled Receptor Dimerization. EMBO Rep. 2004 ; 5: 30-34 (Pubitemid 38228524)
201. Smith N. J., Milligan G.. Allostery at G protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes. Pharmacol. Rev. 2010 ; 62: 701-725
202. George S. R., O'Dowd B. F., Lee S. P.. G-protein-Coupled Receptor Oligomerization and Its Potential for Drug Discovery. Nat. Rev. Drug Discov. 2002 ; 1: 808-820 (Pubitemid 37361564)
203. Gupta A., Mulder J., Gomes I., et al. Increased Abundance of Opioid Receptor Heteromers after Chronic Morphine Administration. Sci. Signal. 2010 ; 3: ra54
204. Frey A. J., Ibrahim S., Gleim S., et al. Biased Suppression of Thromboxane A2 Receptor Homodimerization and Signaling Through Disruption of a Transmembrane GxxxGxxxL Helical Interaction Motif. J. Lipid Res. 2013 ; 54: 1678-1690
205. Dowal L., Flaumenhaft R.. Targeting Platelet G-protein Coupled Receptors (GPCRs): Looking beyond Conventional GPCR Antagonism. Curr. Vasc. Pharmacol. 2010 ; 8: 140-154
206. Kramp B. K., Sarabi A., Koenen R. R., et al. Heterophilic Chemokine Receptor Interactions in Chemokine Signaling and Biology. Exp. Cell Res. 2011 ; 317: 655-663
207. De Poorter C., Baertsoen K., Lannoy V., et al. Consequences of ChemR23 Heteromerization with the Chemokine Receptors CXCR4 and CCR7. PLoS One. 2013 ; 8: e58075
208. Woehler A., Ponimaskin E. G.. G protein-Mediated Signaling: Same Receptor, Multiple Effectors. Curr. Mol. Pharmacol. 2009 ; 2: 237-248
209. Ferré S., Navarro G., Casadó V., et al. G protein-Coupled Receptor Heteromers as New Targets for Drug Development. Prog. Mol. Biol. Transl. Sci. 2010 ; 91: 41-52
210. Schelshorn D., Joly F., Mutel S., et al. Lateral Allosterism in the Glucagon Receptor Family: Glucagon-like Peptide 1 Induces G-protein-Coupled Receptor Heteromer Formation. Mol. Pharmacol. 2012 ; 81: 309-318
211. Holst J. J., Vilsbøll T., Deacon C. F.. The Incretin System and Its Role in Type 2 Diabetes Mellitus. Mol. Cell. Endocrinol. 2009 ; 297: 127-136
212. Magalhaes A. C., Dunn H., Ferguson S. S. G.. Regulation of GPCR Activity, Trafficking and Localization by GPCR-Interacting Proteins. Br. J. Pharmacol. 2012 ; 165: 1717-1736
213. Ladds G., Goddard A., Hill C., et al. Differential Effects of RGS Proteins on G alpha(q) and G alpha(11) Activity. Cell. Signal. 2007 ; 19: 103-113 (Pubitemid 44880247)
214. Sjögren B., Blazer L. L., Neubig R. R.. Regulators of G protein Signaling Proteins as Targets for Drug Discovery. Prog. Mol. Biol. Transl. Sci. 2010 ; 91: 81-119
215. Zhang R., Xie X.. Tools for GPCR Drug Discovery. Acta Pharmacol. Sinica. 2012 ; 33: 372-384
216. Rocheville M., Martin J., Jerman J., et al. Mining the Potential of Label-Free Biosensors for Seven-Transmembrane Receptor Drug Discovery. Prog. Mol. Biol. Transl. Sci. 2013 ; 115: 123-142
217. Hutchings C. J., Koglin M., Marshall F. H.. Therapeutic Antibodies Directed at G protein-Coupled Receptors. mAbs. 2: 594-606